1 Introduction As early as the end of March 2020, reports surfaced that HIV antiretrovirals may have been effective against the virus SARS-CoV-2, potentially preventing severe COVID-19 disease (Johnson 2020a, 2020b, 62–63). These reports speculated about the HIV combination drug, tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC),1 inhibiting replication of SARS-CoV-2 in a similar way to another antiviral, remdesivir (Johnson 2020b).